{"protocolSection":{"identificationModule":{"nctId":"NCT02730455","orgStudyIdInfo":{"id":"101SK202"},"secondaryIdInfos":[{"id":"2015-004783-11","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Biogen","class":"INDUSTRY"},"briefTitle":"Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke","officialTitle":"Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke","acronym":"ACTION2"},"statusModule":{"statusVerifiedDate":"2018-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-07-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-11-20","type":"ACTUAL"},"completionDateStruct":{"date":"2017-11-20","type":"ACTUAL"},"studyFirstSubmitDate":"2016-03-10","studyFirstSubmitQcDate":"2016-04-01","studyFirstPostDateStruct":{"date":"2016-04-06","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-10-18","resultsFirstSubmitQcDate":"2018-12-18","resultsFirstPostDateStruct":{"date":"2019-01-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-12-18","lastUpdatePostDateStruct":{"date":"2019-01-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Biogen","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The primary objective of the study is to assess the clinical effects of natalizumab versus placebo in acute ischemic stroke on clinical measures of functional independence and activities of daily living. The secondary objective of the study is to explore dose and exposure response and the clinical treatment effects of natalizumab versus placebo in acute ischemic stroke on the following: measures of independence, activities of daily living, neurologic function, quality of life, cognition, and safety and tolerability"},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":277,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"natalizumab high dose","type":"EXPERIMENTAL","description":"Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.","interventionNames":["Drug: natalizumab"]},{"label":"natalizumab low dose","type":"EXPERIMENTAL","description":"Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.","interventionNames":["Drug: natalizumab"]},{"label":"Placebo","type":"EXPERIMENTAL","description":"Single dose of Placebo IV at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"natalizumab","description":"Administered as specified in the treatment arm","armGroupLabels":["natalizumab high dose","natalizumab low dose"],"otherNames":["BG00002"]},{"type":"DRUG","name":"Placebo","description":"Matched placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90","description":"The composite global measure of functional disability excellent outcome was based on a score of 0 or 1 on the modified Rankin Scale (mRS) and a score of \\>=95 on the Barthel Index (BI). mRS measures independence, rather than neurological function, with specific tasks pre- and post-stroke. The scale consists of 7 grades, from 0 to 6, with 0 corresponding to no symptoms and 6 corresponding to death. BI consists of 10 items that measure a participant's daily functioning, specifically the activities of daily living and mobility. The items include feeding, moving from wheelchair to bed and returning, grooming, transferring to and from a toilet, bathing, walking on a level surface, going up and down stairs, dressing, and maintaining continence of bowels and bladder. The scores for each of the items are summed to create a total score of 0 to 100. The higher the score, the more \"independent\" the participant is.","timeFrame":"Day 90"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With Excellent Outcome in mRS Score at Day 90","description":"Excellent mRS is defined as mRS score of 0 or 1. mRS measures independence, rather than neurological function, with specific tasks pre- and poststroke. The scale consists of 7 grades, from 0 to 6, with 0 corresponding to no symptoms and 6 corresponding to death.","timeFrame":"Day 90"},{"measure":"Percentage of Participants With Excellent Outcome in BI Score at Day 90","description":"Excellent BI outcome is defined as a score of \\>=95. BI consists of 10 items that measure a participant's daily functioning, specifically the activities of daily living and mobility. The items include feeding, moving from wheelchair to bed and returning, grooming, transferring to and from a toilet, bathing, walking on a level surface, going up and down stairs, dressing, and maintaining continence of bowels and bladder. The scores for each of the items are summed to create a total score of 0 to 100. The higher the score, the more \"independent\" the participant is.","timeFrame":"Day 90"},{"measure":"Stroke Impact Scale-16 (SIS-16) Score Using a Repeated Measures Mixed Effects Model at Day 90","description":"The SIS-16 is a 16-item physical dimension instrument that was developed as a brief, stand-alone tool for measuring the physical aspects of stroke recovery. The 16 physical aspects are rated on a 1 to 5 scale as follows: not difficult at all (5), a little difficult (4), somewhat difficult (3), very difficult (2), and could not do at all (1). Total score range is 16 to 80, with higher scores indicating higher levels of health-related quality of life and function.","timeFrame":"Day 90"},{"measure":"Montreal Cognitive Assessment (MoCA) Score at Day 90","description":"The MoCA is a global cognitive screening test with favorable psychometric properties It screens 8 domains: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall, and orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 0 to 30 points; a score of 26 or above is considered normal, \\<10 (severe cognitive impairment), 10-17 (moderate cognitive impairment) and \\>=18 (mild cognitive impairment).","timeFrame":"Day 90"},{"measure":"Change From Baseline in National Institute of Health Stroke Scale (NIHSS) Score at Day 90","description":"The NIHSS is a reliable tool for rapidly evaluating the effects of acute cerebral infarction. A trained observer rates the participant's ability to answer questions and perform activities relating to level of consciousness, language, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, sensory loss, and extinction and inattention (formerly neglect). There are 15 items. Total score ranges from 0 as normal to a maximum possible total severity score of 42 for all items. Higher the score, more the severity. A negative change from Baseline indicates improvement.","timeFrame":"Baseline, Day 90"},{"measure":"Number of Participants Experiencing Adverse Events (AE)","description":"An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.","timeFrame":"Baseline up to Day 90"},{"measure":"Number of Participants Experiencing Serious Adverse Events (SAE)","description":"A SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization, results in a significant disability/incapacity or congenital anomaly.","timeFrame":"Baseline up to Day 90"},{"measure":"Percentage of Participants With Dose Response at Day 90","description":"Percentage of participants with dose response was evaluated in proportion of excellent outcome on mRS and BI.","timeFrame":"Day 90"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Clinical diagnosis of supratentorial acute ischemic stroke defined by LKN ≤24 hours prior to study treatment initiation.\n* Score of 5 to 23 points, inclusive, on the NIHSS at Screening for subjects initiating treatment ≤9 hours from LKN. Note: NIHSS eligibility must be confirmed within 60 minutes prior to randomization.\n* Score of 5 to 15 points, inclusive, on the NIHSS at Screening for subjects initiating treatment \\>9 to ≤24 hours from LKN. Note: NIHSS eligibility must be confirmed within 60 minutes prior to randomization.\n* Prior to index stroke, patient was able to perform basic activities of daily living without assistance: dressing, eating, walking, bathing, and using the toilet.\n* For those subjects who underwent a cranial MRI, there is at least 1 acute infarct with a diameter of ≥2 cm on baseline brain diffusion-weighted imaging.\n\nKey Exclusion Criteria:\n\n* Lacunar or isolated brainstem or cerebellar stroke based on clinical assessment and available acute imaging studies performed under the standard of care.\n* Presence of acute intracranial hemorrhage on acute brain CT or MRI. However, petechial hemorrhages of ≤1 cm are not exclusionary.\n* Severe stroke defined by imaging criteria based on either one of the following:\n* Alberta Stroke Program Early CT (ASPECT) score of 0 to 4 based on head CT or\n* Acute infarct volume on MRI diffusion weighed imaging greater than or equal to 70 mL\n* Seizure at the onset of stroke.\n* Known history of prior treatment with natalizumab.\n* Known history of active viral hepatitis B or C.\n* Signs and symptoms of active or acute infection.\n\nNOTE: Other protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Biogen","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"Los Angeles","state":"California","zip":"90024","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Research Site","city":"Sacramento","state":"California","zip":"95816","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Research Site","city":"San Diego","state":"California","zip":"92103","country":"United States","geoPoint":{"lat":32.71533,"lon":-117.15726}},{"facility":"Research Site","city":"Washington","state":"District of Columbia","zip":"20007","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Research Site","city":"Gainesville","state":"Florida","zip":"32611","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"Research Site","city":"Fort Wayne","state":"Indiana","zip":"46845","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"Research Site","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Research Site","city":"Saint Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Research Site","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Research Site","city":"Durham","state":"North Carolina","zip":"19104","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Research Site","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Research Site","city":"Portland","state":"Oregon","zip":"97201","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Research Site","city":"Portland","state":"Oregon","zip":"97225","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Research Site","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Research Site","city":"Abington","state":"Pennsylvania","zip":"19001","country":"United States","geoPoint":{"lat":40.12067,"lon":-75.11795}},{"facility":"Research Site","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"Research Site","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77657,"lon":-79.93092}},{"facility":"Research Site","city":"Knoxville","state":"Tennessee","zip":"37920-6999","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Research Site","city":"Altenburg","zip":"04600","country":"Germany","geoPoint":{"lat":50.98763,"lon":12.43684}},{"facility":"Research Site","city":"Bad Neustadt/Saale","zip":"97616","country":"Germany"},{"facility":"Research Site","city":"Bamberg","zip":"96049","country":"Germany","geoPoint":{"lat":49.89873,"lon":10.90067}},{"facility":"Research Site","city":"Bergisch Gladbach","zip":"51465","country":"Germany","geoPoint":{"lat":50.9856,"lon":7.13298}},{"facility":"Research Site","city":"Dresden","zip":"01067","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"Research Site","city":"Dresden","zip":"01307","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"Research Site","city":"Duesseldorf","zip":"40225","country":"Germany","geoPoint":{"lat":51.22172,"lon":6.77616}},{"facility":"Research Site","city":"Erlangen","zip":"91054","country":"Germany","geoPoint":{"lat":49.59099,"lon":11.00783}},{"facility":"Research Site","city":"Frankfurt","zip":"60528","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Research Site","city":"Hamburg","zip":"20246","country":"Germany","geoPoint":{"lat":53.57532,"lon":10.01534}},{"facility":"Research Site","city":"Heidelberg","zip":"69120","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Research Site","city":"Leipzig","zip":"04103","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Research Site","city":"Ludwigshafen","zip":"67063","country":"Germany","geoPoint":{"lat":49.48121,"lon":8.44641}},{"facility":"Research Site","city":"Mannheim","zip":"68167","country":"Germany","geoPoint":{"lat":49.4891,"lon":8.46694}},{"facility":"Research Site","city":"Minden","zip":"32429","country":"Germany","geoPoint":{"lat":52.28953,"lon":8.91455}},{"facility":"Research Site","city":"Muenster","zip":"48149","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}},{"facility":"Research Site","city":"Trier","zip":"54292","country":"Germany","geoPoint":{"lat":49.75565,"lon":6.63935}},{"facility":"Research Site","city":"Tuebingen","zip":"72076","country":"Germany","geoPoint":{"lat":48.52266,"lon":9.05222}},{"facility":"Research Site","city":"Ulm","zip":"89081","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"Research Site","city":"Albacete","zip":"02008","country":"Spain","geoPoint":{"lat":38.99424,"lon":-1.85643}},{"facility":"Research Site","city":"Badalona","zip":"08916","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Research Site","city":"Barcelona","zip":"08003","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Girona","zip":"17007","country":"Spain","geoPoint":{"lat":41.98311,"lon":2.82493}},{"facility":"Research Site","city":"Lugo","zip":"27003","country":"Spain","geoPoint":{"lat":43.00992,"lon":-7.55602}},{"facility":"Research Site","city":"Madrid","zip":"28007","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Madrid","zip":"28034","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Malaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Research Site","city":"Sevilla","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Research Site","city":"Sevilla","zip":"41017","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Research Site","city":"Valladolid","zip":"47005","country":"Spain","geoPoint":{"lat":41.65518,"lon":-4.72372}},{"facility":"Research Site","city":"London","state":"Greater London","zip":"SW17 0QT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Research Site","city":"London","state":"Greater London","zip":"W6 8RF","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Research Site","city":"Harrow","state":"Middlesex","zip":"HA1 3UJ","country":"United Kingdom","geoPoint":{"lat":51.57142,"lon":-0.33371}},{"facility":"Research Site","city":"Stoke on Trent","state":"Staffordshire","zip":"ST4 6QG","country":"United Kingdom","geoPoint":{"lat":53.00415,"lon":-2.18538}}]},"referencesModule":{"references":[{"pmid":"32591475","type":"DERIVED","citation":"Elkind MSV, Veltkamp R, Montaner J, Johnston SC, Singhal AB, Becker K, Lansberg MG, Tang W, Kasliwal R, Elkins J. Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial. Neurology. 2020 Aug 25;95(8):e1091-e1104. doi: 10.1212/WNL.0000000000010038. Epub 2020 Jun 26."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 277 participants with acute ischemic stroke were randomized into the study (94 participants in the placebo group, 91 participants in the natalizumab 300 milligram (mg) group, and 92 participants in the natalizumab 600 mg group).","recruitmentDetails":"Participants were recruited from 19 sites in Germany, 4 sites in the United Kingdom (UK), 12 sites in Spain, and 18 sites in the United States (US).","groups":[{"id":"FG000","title":"Placebo","description":"Single dose of matching placebo intravenous (IV) to natalizumab on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"FG001","title":"Natalizumab 300 mg IV","description":"Single 300 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"FG002","title":"Natalizumab 600 mg IV","description":"Single 600 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"94"},{"groupId":"FG001","numSubjects":"91"},{"groupId":"FG002","numSubjects":"92"}]},{"type":"Safety Population","comment":"Participants who had received any study treatment (including complete or incomplete infusion)","achievements":[{"groupId":"FG000","numSubjects":"91"},{"groupId":"FG001","numSubjects":"90"},{"groupId":"FG002","numSubjects":"89"}]},{"type":"Participants Dosed","achievements":[{"groupId":"FG000","numSubjects":"91"},{"groupId":"FG001","numSubjects":"88"},{"groupId":"FG002","numSubjects":"91"}]},{"type":"Who Received Total Volume of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"90"},{"groupId":"FG001","numSubjects":"88"},{"groupId":"FG002","numSubjects":"89"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"81"},{"groupId":"FG001","numSubjects":"77"},{"groupId":"FG002","numSubjects":"81"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"11"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"Consent withdrawn","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intent-to-treat (ITT) population included all participants who were randomized.","groups":[{"id":"BG000","title":"Placebo","description":"Single dose of matching placebo intravenous (IV) to natalizumab on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"BG001","title":"Natalizumab 300 mg IV","description":"Single 300 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"BG002","title":"Natalizumab 600 mg IV","description":"Single 600 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"94"},{"groupId":"BG001","value":"91"},{"groupId":"BG002","value":"92"},{"groupId":"BG003","value":"277"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"67.1","spread":"9.54"},{"groupId":"BG001","value":"66.1","spread":"10.47"},{"groupId":"BG002","value":"65.6","spread":"11.09"},{"groupId":"BG003","value":"66.2","spread":"10.36"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"37"},{"groupId":"BG003","value":"102"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"175"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"7"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"76"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"194"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"count of participants","classes":[{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"77"}]}]},{"title":"Not Reported Due to Confidentiality Regulations","categories":[{"measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"194"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90","description":"The composite global measure of functional disability excellent outcome was based on a score of 0 or 1 on the modified Rankin Scale (mRS) and a score of \\>=95 on the Barthel Index (BI). mRS measures independence, rather than neurological function, with specific tasks pre- and post-stroke. The scale consists of 7 grades, from 0 to 6, with 0 corresponding to no symptoms and 6 corresponding to death. BI consists of 10 items that measure a participant's daily functioning, specifically the activities of daily living and mobility. The items include feeding, moving from wheelchair to bed and returning, grooming, transferring to and from a toilet, bathing, walking on a level surface, going up and down stairs, dressing, and maintaining continence of bowels and bladder. The scores for each of the items are summed to create a total score of 0 to 100. The higher the score, the more \"independent\" the participant is.","populationDescription":"Modified Intent-to-Treat (MITT) population: all randomized participants who had received entire infusion of study treatment. Participants who were accidentally enrolled based on conditions that mimicked stroke symptom at presentation were excluded from MITT population. Number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Placebo","description":"Single dose of matching placebo intravenous (IV) to natalizumab on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG001","title":"Natalizumab 300 mg IV","description":"Single 300 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG002","title":"Natalizumab 600 mg IV","description":"Single 600 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"88"},{"groupId":"OG002","value":"89"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1"},{"groupId":"OG001","value":"41.5"},{"groupId":"OG002","value":"39.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Composite Measure: The global odds ratio was based on a linear logistic regression model with baseline National Institute of Health Stroke Scale (NIHSS) category (score 5-15, 16-23), age (\\<60, 60-69, 70-80), tissue plasminogen activator (tPA) use (yes/no), treatment window (\\<=9, \\>9 and \\<=24hours), thrombectomy (yes/no) and region (Spain, UK/Germany, United States of America \\[USA\\]) as covariates and unstructured working correlation structure","nonInferiorityType":"SUPERIORITY","pValue":"0.086","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.38","ciUpperLimit":"1.07"},{"groupIds":["OG000","OG002"],"groupDescription":"Composite Measure: The global odds ratio was based on a linear logistic regression model with baseline NIHSS category (score 5-15, 16-23), age (\\<60, 60-69, 70-80), tPA use (yes/no), treatment window (\\<=9, \\>9 and \\<=24hours), thrombectomy (yes/no) and region (Spain, UK/Germany, USA) as covariates and unstructured working correlation structure","nonInferiorityType":"SUPERIORITY","pValue":"0.031","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.34","ciUpperLimit":"0.95"}]},{"type":"SECONDARY","title":"Percentage of Participants With Excellent Outcome in mRS Score at Day 90","description":"Excellent mRS is defined as mRS score of 0 or 1. mRS measures independence, rather than neurological function, with specific tasks pre- and poststroke. The scale consists of 7 grades, from 0 to 6, with 0 corresponding to no symptoms and 6 corresponding to death.","populationDescription":"MITT population: all randomized participants who had received entire infusion of study treatment. Participants who were accidentally enrolled based on conditions that mimicked stroke symptom at presentation were excluded from MITT population. Number analyzed is number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Placebo","description":"Single dose of matching placebo intravenous (IV) to natalizumab on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG001","title":"Natalizumab 300 mg IV","description":"Single 300 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG002","title":"Natalizumab 600 mg IV","description":"Single 600 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"82"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"26"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The odds ratio was based on a linear logistic regression model with baseline NIHSS category (score 5-15, 16-23), age (\\<60, 60-69, 70-80), tPA use (yes/no), treatment window (\\<=9, \\>9 and \\<=24hours), thrombectomy (yes/no) and region (Spain, UK/Germany, USA) as covariates and unstructured working correlation structure","nonInferiorityType":"SUPERIORITY","pValue":"0.222","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.67","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.35","ciUpperLimit":"1.28"},{"groupIds":["OG000","OG002"],"groupDescription":"The odds ratio was based on a linear logistic regression model with baseline NIHSS category (score 5-15, 16-23), age (\\<60, 60-69, 70-80), tPA use (yes/no), treatment window (\\<=9, \\>9 and \\<=24hours), thrombectomy (yes/no) and region (Spain, UK/Germany, USA) as covariates and unstructured working correlation structure","nonInferiorityType":"SUPERIORITY","pValue":"0.073","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.54","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.28","ciUpperLimit":"1.06"}]},{"type":"SECONDARY","title":"Percentage of Participants With Excellent Outcome in BI Score at Day 90","description":"Excellent BI outcome is defined as a score of \\>=95. BI consists of 10 items that measure a participant's daily functioning, specifically the activities of daily living and mobility. The items include feeding, moving from wheelchair to bed and returning, grooming, transferring to and from a toilet, bathing, walking on a level surface, going up and down stairs, dressing, and maintaining continence of bowels and bladder. The scores for each of the items are summed to create a total score of 0 to 100. The higher the score, the more \"independent\" the participant is.","populationDescription":"MITT population: all randomized participants who had received entire infusion of study treatment. Participants who were accidentally enrolled based on conditions that mimicked stroke symptom at presentation were excluded from MITT population. Number analyzed is number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Placebo","description":"Single dose of matching placebo intravenous (IV) to natalizumab on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG001","title":"Natalizumab 300 mg IV","description":"Single 300 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG002","title":"Natalizumab 600 mg IV","description":"Single 600 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"81"},{"groupId":"OG002","value":"81"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"54"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The odds ratio was based on a linear logistic regression model with baseline NIHSS category (score 5-15, 16-23), age (\\<60, 60-69, 70-80), tPA use (yes/no), treatment window (\\<=9, \\>9 and \\<=24hours), thrombectomy (yes/no) and region (Spain, UK/Germany, USA) as covariates and unstructured working correlation structure.","nonInferiorityType":"SUPERIORITY","pValue":"0.085","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.56","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.29","ciUpperLimit":"1.08"},{"groupIds":["OG000","OG002"],"groupDescription":"The odds ratio was based on a linear logistic regression model with baseline NIHSS category (score 5-15, 16-23), age (\\<60, 60-69, 70-80), tPA use (yes/no), treatment window (\\<=9, \\>9 and \\<=24hours), thrombectomy (yes/no) and region (Spain, UK/Germany, USA) as covariates and unstructured working correlation structure.","nonInferiorityType":"SUPERIORITY","pValue":"0.067","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.54","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.28","ciUpperLimit":"1.04"}]},{"type":"SECONDARY","title":"Stroke Impact Scale-16 (SIS-16) Score Using a Repeated Measures Mixed Effects Model at Day 90","description":"The SIS-16 is a 16-item physical dimension instrument that was developed as a brief, stand-alone tool for measuring the physical aspects of stroke recovery. The 16 physical aspects are rated on a 1 to 5 scale as follows: not difficult at all (5), a little difficult (4), somewhat difficult (3), very difficult (2), and could not do at all (1). Total score range is 16 to 80, with higher scores indicating higher levels of health-related quality of life and function.","populationDescription":"MITT population: all randomized participants who had received entire infusion of study treatment. Participants who were accidentally enrolled based on conditions that mimicked stroke symptom at presentation were excluded from MITT population. Number analyzed is number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Placebo","description":"Single dose of matching placebo intravenous (IV) to natalizumab on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG001","title":"Natalizumab 300 mg IV","description":"Single 300 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG002","title":"Natalizumab 600 mg IV","description":"Single 600 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"77"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.21","spread":"30.783"},{"groupId":"OG001","value":"66.96","spread":"35.493"},{"groupId":"OG002","value":"68.10","spread":"31.461"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment and treatment by visit interaction were included in the model as explanatory variables. Baseline NIHSS category (score 5-15, 16-23), tPA use (yes/no), age (\\<60, 60-69, 70-80), thrombectomy (yes/no), region (Spain, UK/Germany, USA) and treatment window were considered as covariates. An unstructured variance-covariance matrix was used in the model.","nonInferiorityType":"SUPERIORITY","pValue":"0.106","statisticalMethod":"Mixed-effects model for repeated measure","paramType":"Adjusted Mean Difference","paramValue":"-7.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-16.97","ciUpperLimit":"1.64"},{"groupIds":["OG000","OG002"],"groupDescription":"Treatment and treatment by visit interaction were included in the model as explanatory variables. Baseline NIHSS category (score 5-15, 16-23), tPA use (yes/no), age (\\<60, 60-69, 70-80), thrombectomy (yes/no), region (Spain, UK/Germany, USA) and treatment window were considered as covariates. An unstructured variance-covariance matrix was used in the model.","nonInferiorityType":"SUPERIORITY","pValue":"0.202","statisticalMethod":"Mixed-effects model for repeated measure","paramType":"Adjusted Mean Difference","paramValue":"-6.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-15.43","ciUpperLimit":"3.27"}]},{"type":"SECONDARY","title":"Montreal Cognitive Assessment (MoCA) Score at Day 90","description":"The MoCA is a global cognitive screening test with favorable psychometric properties It screens 8 domains: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall, and orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 0 to 30 points; a score of 26 or above is considered normal, \\<10 (severe cognitive impairment), 10-17 (moderate cognitive impairment) and \\>=18 (mild cognitive impairment).","populationDescription":"MITT population: all randomized participants who had received entire infusion of study treatment. Participants who were accidentally enrolled based on conditions that mimicked stroke symptom at presentation were excluded from MITT population. Number analyzed is number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Placebo","description":"Single dose of matching placebo intravenous (IV) to natalizumab on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG001","title":"Natalizumab 300 mg IV","description":"Single 300 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG002","title":"Natalizumab 600 mg IV","description":"Single 600 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"69"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.23","spread":"8.412"},{"groupId":"OG001","value":"20.73","spread":"8.141"},{"groupId":"OG002","value":"20.90","spread":"8.223"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment and treatment by visit interaction were included in the model as explanatory variables. Baseline NIHSS category (score 5-15, 16-23), tPA use (yes/no), age (\\<60, 60-69, 70-80), thrombectomy (yes/no), region (Spain, UK/Germany, USA) and treatment window were considered as covariates. An unstructured variance-covariance matrix was used in the model.","nonInferiorityType":"SUPERIORITY","pValue":"0.780","statisticalMethod":"Mixed-effects model for repeated measure","paramType":"Adjusted Mean Difference","paramValue":"-0.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.64","ciUpperLimit":"1.99"},{"groupIds":["OG000","OG002"],"groupDescription":"Treatment and treatment by visit interaction were included in the model as explanatory variables. Baseline NIHSS category (score 5-15, 16-23), tPA use (yes/no), age (\\<60, 60-69, 70-80), thrombectomy (yes/no), region (Spain, UK/Germany, USA) and treatment window were considered as covariates. An unstructured variance-covariance matrix was used in the model.","nonInferiorityType":"SUPERIORITY","pValue":"0.622","statisticalMethod":"Mixed-effects model for repeated measure","paramType":"Adjusted Mean Difference","paramValue":"-0.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.89","ciUpperLimit":"1.73"}]},{"type":"SECONDARY","title":"Change From Baseline in National Institute of Health Stroke Scale (NIHSS) Score at Day 90","description":"The NIHSS is a reliable tool for rapidly evaluating the effects of acute cerebral infarction. A trained observer rates the participant's ability to answer questions and perform activities relating to level of consciousness, language, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, sensory loss, and extinction and inattention (formerly neglect). There are 15 items. Total score ranges from 0 as normal to a maximum possible total severity score of 42 for all items. Higher the score, more the severity. A negative change from Baseline indicates improvement.","populationDescription":"MITT population: all randomized participants who had received entire infusion of study treatment. Participants who were accidentally enrolled based on conditions that mimicked stroke symptom at presentation were excluded from MITT population. Number analyzed is number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Day 90","groups":[{"id":"OG000","title":"Placebo","description":"Single dose of matching placebo intravenous (IV) to natalizumab on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG001","title":"Natalizumab 300 mg IV","description":"Single 300 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG002","title":"Natalizumab 600 mg IV","description":"Single 600 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"71"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.14","spread":"6.920"},{"groupId":"OG001","value":"-5.17","spread":"7.937"},{"groupId":"OG002","value":"-6.28","spread":"6.510"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment and treatment by visit interaction were included in the model as explanatory variables. Baseline NIHSS category (score 5-15, 16-23), tPA use (yes/no), age (\\<60, 60-69, 70-80), thrombectomy (yes/no), region (Spain, UK/Germany, USA) and treatment window were considered as covariates. An unstructured variance-covariance matrix was used in the model.","nonInferiorityType":"SUPERIORITY","pValue":"0.315","statisticalMethod":"Mixed-effects model for repeated measure","paramType":"Adjusted Mean Difference","paramValue":"1.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.10","ciUpperLimit":"3.40"},{"groupIds":["OG000","OG002"],"groupDescription":"Treatment and treatment by visit interaction were included in the model as explanatory variables. Baseline NIHSS category (score 5-15, 16-23), tPA use (yes/no), age (\\<60, 60-69, 70-80), thrombectomy (yes/no), region (Spain, UK/Germany, USA) and treatment window were considered as covariates. An unstructured variance-covariance matrix was used in the model.","nonInferiorityType":"SUPERIORITY","pValue":"0.542","statisticalMethod":"Mixed-effects model for repeated measure","paramType":"Adjusted Mean Difference","paramValue":"-0.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.96","ciUpperLimit":"1.56"}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Adverse Events (AE)","description":"An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.","populationDescription":"The safety population was defined as participants who had received any study treatment, including cases of complete or incomplete infusion.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline up to Day 90","groups":[{"id":"OG000","title":"Placebo","description":"Single dose of matching placebo intravenous (IV) to natalizumab on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG001","title":"Natalizumab 300 mg IV","description":"Single 300 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG002","title":"Natalizumab 600 mg IV","description":"Single 600 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"89"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"81"},{"groupId":"OG002","value":"82"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Serious Adverse Events (SAE)","description":"A SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization, results in a significant disability/incapacity or congenital anomaly.","populationDescription":"The safety population was defined as participants who had received any study treatment, including cases of complete or incomplete infusion.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline up to Day 90","groups":[{"id":"OG000","title":"Placebo","description":"Single dose of matching placebo intravenous (IV) to natalizumab on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG001","title":"Natalizumab 300 mg IV","description":"Single 300 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG002","title":"Natalizumab 600 mg IV","description":"Single 600 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"89"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"29"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Dose Response at Day 90","description":"Percentage of participants with dose response was evaluated in proportion of excellent outcome on mRS and BI.","populationDescription":"MITT population: all randomized participants who had received entire infusion of study treatment. Participants who were accidentally enrolled based on conditions that mimicked stroke symptom at presentation were excluded from MITT population. Number analyzed is number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Placebo","description":"Single dose of matching placebo intravenous (IV) to natalizumab on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG001","title":"Natalizumab 300 mg IV","description":"Single 300 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."},{"id":"OG002","title":"Natalizumab 600 mg IV","description":"Single 600 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"88"},{"groupId":"OG002","value":"89"}]}],"classes":[{"title":"mRS (0, 1)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"82"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"26"}]}]},{"title":"BI (>=95)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"81"},{"groupId":"OG002","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"54"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"groupDescription":"mRS: The Cochran-Armitage trend test of a monotonically increasing dose response in proportion of excellent outcome.\n\nDose levels are log transformed.","nonInferiorityType":"SUPERIORITY","pValue":"0.028","statisticalMethod":"Cochran-Armitage trend test"},{"groupIds":["OG000","OG001","OG002"],"groupDescription":"BI: The Cochran-Armitage trend test of a monotonically increasing dose response in proportion of excellent outcome. Dose levels are log transformed.","nonInferiorityType":"SUPERIORITY","pValue":"0.049","statisticalMethod":"Cochran-Armitage trend test"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline up to Day 90","description":"The safety population was defined as participants who had received any study treatment, including cases of complete or incomplete infusion.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Single dose of matching placebo intravenous (IV) to natalizumab on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN).","deathsNumAffected":5,"deathsNumAtRisk":91,"seriousNumAffected":19,"seriousNumAtRisk":91,"otherNumAffected":67,"otherNumAtRisk":91},{"id":"EG001","title":"Natalizumab 300 mg IV","description":"Single 300 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN).","deathsNumAffected":6,"deathsNumAtRisk":90,"seriousNumAffected":23,"seriousNumAtRisk":90,"otherNumAffected":69,"otherNumAtRisk":90},{"id":"EG002","title":"Natalizumab 600 mg IV","description":"Single 600 mg natalizumab IV on Day 1 at one of two treatment windows, either within 9 hours or between 9-24 hours from when the participant was last known normal (LKN).","deathsNumAffected":4,"deathsNumAtRisk":89,"seriousNumAffected":29,"seriousNumAtRisk":89,"otherNumAffected":65,"otherNumAtRisk":89}],"seriousEvents":[{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":2,"numAtRisk":89}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Cardiogenic shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Coronary artery stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Sinus node dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Ileus paralytic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Oesophageal ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Retroperitoneal haematoma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Ischaemic hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Endocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Endocarditis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Enterococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Febrile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Haemophilus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Pneumonia acinetobacter","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Septic encephalopathy","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Splenic abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Wound infection staphylococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Aortic restenosis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Brain herniation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Ilium fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Periprocedural myocardial infarction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Post procedural complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Wound dehiscence","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Escherichia test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Hyperglycaemic hyperosmolar nonketotic syndrome","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Pancreatic carcinoma stage IV","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Cerebral artery occlusion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":2,"numAtRisk":89}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":3,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":2,"numAtRisk":89}]},{"term":"Cerebral reperfusion injury","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":3,"numAtRisk":89}]},{"term":"Cytotoxic oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Embolic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Generalised tonic-clonic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Haemorrhagic transformation stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":3,"numAtRisk":90},{"groupId":"EG002","numAffected":2,"numAtRisk":89}]},{"term":"Lacunar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Neurological decompensation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Stroke in evolution","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":2,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":2,"numAtRisk":89}]},{"term":"Ureteric rupture","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":2,"numAtRisk":89}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Haemothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":2,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":3,"numAtRisk":90},{"groupId":"EG002","numAffected":3,"numAtRisk":89}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":2,"numAtRisk":89}]},{"term":"Idiopathic angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Aortic embolus","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Peripheral artery occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":0,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":91},{"groupId":"EG001","numAffected":3,"numAtRisk":90},{"groupId":"EG002","numAffected":5,"numAtRisk":89}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":91},{"groupId":"EG001","numAffected":6,"numAtRisk":90},{"groupId":"EG002","numAffected":7,"numAtRisk":89}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":5,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":91},{"groupId":"EG001","numAffected":19,"numAtRisk":90},{"groupId":"EG002","numAffected":23,"numAtRisk":89}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":91},{"groupId":"EG001","numAffected":5,"numAtRisk":90},{"groupId":"EG002","numAffected":3,"numAtRisk":89}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":91},{"groupId":"EG001","numAffected":6,"numAtRisk":90},{"groupId":"EG002","numAffected":2,"numAtRisk":89}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":91},{"groupId":"EG001","numAffected":7,"numAtRisk":90},{"groupId":"EG002","numAffected":6,"numAtRisk":89}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":91},{"groupId":"EG001","numAffected":7,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":91},{"groupId":"EG001","numAffected":7,"numAtRisk":90},{"groupId":"EG002","numAffected":2,"numAtRisk":89}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":91},{"groupId":"EG001","numAffected":19,"numAtRisk":90},{"groupId":"EG002","numAffected":14,"numAtRisk":89}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":91},{"groupId":"EG001","numAffected":2,"numAtRisk":90},{"groupId":"EG002","numAffected":8,"numAtRisk":89}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":91},{"groupId":"EG001","numAffected":14,"numAtRisk":90},{"groupId":"EG002","numAffected":15,"numAtRisk":89}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":91},{"groupId":"EG001","numAffected":7,"numAtRisk":90},{"groupId":"EG002","numAffected":5,"numAtRisk":89}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":91},{"groupId":"EG001","numAffected":12,"numAtRisk":90},{"groupId":"EG002","numAffected":6,"numAtRisk":89}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":91},{"groupId":"EG001","numAffected":1,"numAtRisk":90},{"groupId":"EG002","numAffected":5,"numAtRisk":89}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":91},{"groupId":"EG001","numAffected":5,"numAtRisk":90},{"groupId":"EG002","numAffected":2,"numAtRisk":89}]},{"term":"Haemorrhagic transformation stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":91},{"groupId":"EG001","numAffected":4,"numAtRisk":90},{"groupId":"EG002","numAffected":5,"numAtRisk":89}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":91},{"groupId":"EG001","numAffected":16,"numAtRisk":90},{"groupId":"EG002","numAffected":20,"numAtRisk":89}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":91},{"groupId":"EG001","numAffected":5,"numAtRisk":90},{"groupId":"EG002","numAffected":0,"numAtRisk":89}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":91},{"groupId":"EG001","numAffected":2,"numAtRisk":90},{"groupId":"EG002","numAffected":7,"numAtRisk":89}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":91},{"groupId":"EG001","numAffected":13,"numAtRisk":90},{"groupId":"EG002","numAffected":10,"numAtRisk":89}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":91},{"groupId":"EG001","numAffected":11,"numAtRisk":90},{"groupId":"EG002","numAffected":10,"numAtRisk":89}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":91},{"groupId":"EG001","numAffected":3,"numAtRisk":90},{"groupId":"EG002","numAffected":3,"numAtRisk":89}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":91},{"groupId":"EG001","numAffected":4,"numAtRisk":90},{"groupId":"EG002","numAffected":3,"numAtRisk":89}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":91},{"groupId":"EG001","numAffected":5,"numAtRisk":90},{"groupId":"EG002","numAffected":1,"numAtRisk":89}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":91},{"groupId":"EG001","numAffected":7,"numAtRisk":90},{"groupId":"EG002","numAffected":8,"numAtRisk":89}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":91},{"groupId":"EG001","numAffected":4,"numAtRisk":90},{"groupId":"EG002","numAffected":7,"numAtRisk":89}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication."},"pointOfContact":{"title":"Biogen Study Medical Director","organization":"Biogen","email":"clinicaltrials@biogen.com","phone":"866-633-4636"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-05-19","uploadDate":"2018-12-18T10:41","filename":"Prot_000.pdf","size":1078266},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2017-12-05","uploadDate":"2018-12-18T10:41","filename":"SAP_001.pdf","size":1530859}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069442","term":"Natalizumab"}],"ancestors":[{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M411","name":"Natalizumab","asFound":"Adult diffuse small cleaved cell lymphoma","relevance":"HIGH"},{"id":"M9891","name":"Immunologic Factors","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}